Education
About Us
Working with TipRanks
Follow Us
IRLAB Therapeutics AB Class A (DE:6IRA)
:6IRA
RESEARCH TOOLSreports
Total Valuation
IRLAB Therapeutics AB Class A has a market cap or net worth of €32.93M. The enterprise value is €551.09M.
Market Cap€32.93M
Enterprise Value€551.09M
Share Statistics
IRLAB Therapeutics AB Class A has 51,788,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,788,630
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
IRLAB Therapeutics AB Class A’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee3.05M
Profits Per Employee-2.42M
Employee Count31
Asset Turnover0.69
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of IRLAB Therapeutics AB Class A is -6.71. IRLAB Therapeutics AB Class A’s PEG ratio is 0.13.
PE Ratio-6.71
PS Ratio9.07
PB Ratio17.09
Price to Fair Value17.09
Price to FCF-8.48
Price to Operating Cash Flow-8.50
PEG Ratio0.13
Income Statement
In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 94.63M and earned -83.13M in profits. Earnings per share was -1.60.
Revenue94.63M
Gross Profit94.63M
Operating Income-75.11M
Pretax Income-83.13M
Net Income-83.13M
EBITDA-68.07M
Earnings Per Share (EPS)-1.60
Cash Flow
In the last 12 months, operating cash flow was -65.59M and capital expenditures -199.00K, giving a free cash flow of -65.79M billion.
Operating Cash Flow-65.59M
Free Cash Flow-65.79M
Free Cash Flow per Share-1.27
Dividends & Yields
IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.22
52-Week Price Change-31.87%
50-Day Moving Average0.84
200-Day Moving Average1.09
Relative Strength Index (RSI)42.16
Average Volume (3m)0.00
Important Dates
IRLAB Therapeutics AB Class A upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateFeb 12, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 185.15%
Current Ratio0.80
Quick Ratio0.80
Debt to Market Cap0.10
Net Debt to EBITDA―
Interest Coverage Ratio-7.17
Taxes
In the past 12 months, IRLAB Therapeutics AB Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
IRLAB Therapeutics AB Class A EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
IRLAB Therapeutics AB Class A has €66.92M in cash and marketable securities with kr5.71M in debt, giving a net cash position of -€6.50M billion.
Cash & Marketable Securities€66.92M
Total Debtkr5.71M
Net Cash-€6.50M
Net Cash Per Share-€0.13
Tangible Book Value Per Share€0.63
Margins
Gross margin is -4.82%, with operating margin of -79.38%, and net profit margin of -87.85%.
Gross Margin-4.82%
Operating Margin-79.38%
Pretax Margin-87.85%
Net Profit Margin-87.85%
EBITDA Margin-71.93%
EBIT Margin-76.78%
Analyst Forecast
The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―